BEIJING, April 16 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it will conduct a conference call at 9:00 a.m. Eastern Time on Thursday, April 17, 2008 to discuss the fourth quarter and fiscal year 2007 results.
Joining Mr. Zhongyi Liu, Chief Executive Officer and President of Lotus Pharmaceuticals, Inc., will be Mr. Adam Wasserman, Chief Financial Officer. The Company plans to issue an earnings announcement prior to the call.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 800-688-0796. International callers should dial 617-614-4070. The Conference Passcode for this call is 615 756 86.
If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Thursday, April 17, 2008 at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010, international callers dial 617-801-6888, Conference Passcode 35016441.
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Liangfang
Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd.
("Enze"), two Chinese pharmaceutical companies located in Beijing.
Liangfang and Enze form a large comprehensive enterprise, which deals in an
integration of the production, trade, sales and marketing of
pharmaceuticals. Together, they possess some of the most advanced
pharmaceutical-production equipment used in China, workshops authenticated
by the National GMP, a suite of various medicines produced by Liangfang
and/or Enze (together, "Lotus East"), and a number of high-tech personnel.
Lotus East has business and office facilities of 2,000 square meters,
warehouse of 1,000 square meters and operates ten retail pharmacies in the
Beijing area. Lot
'/>"/>
| SOURCE Lotus Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |